<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01213082</url>
  </required_header>
  <id_info>
    <org_study_id>223071</org_study_id>
    <nct_id>NCT01213082</nct_id>
  </id_info>
  <brief_title>ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)</brief_title>
  <acronym>PBAMD2</acronym>
  <official_title>Phase I/II Prospective, Randomized, Double-blinded Study of Intravitreal Anti-VEGF Therapy Combined With Proton Beam Radiation Versus Sham Irradiation in Treating Exudative Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the hypothesis that proton beam irradiation combined
      with intravitreal anti-VEGF therapy is safe and potentially more effective than intravitreal
      anti-VEGF therapy alone in eyes with exudative age-related macular degeneration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiation combined with anti-VEGF therapy has been shown to be synergistic in treating cancer
      and result in sustained tumor regression. On-going clinical trials have shown potential
      synergism between intravitreal anti-VEGF therapy and epiretinal brachytherapy administered
      during vitrectomy surgery in treating eyes with exudative age-related macular degeneration
      (eAMD). In this study, we test the hypothesis that radiation to the macula administered
      noninvasively via proton beam is well-tolerated in eyes with eAMD when combined with
      intravitreal anti-VEGF therapy and that this combination therapy may act synergistically to
      result in sustained treatment effect in eyes with eAMD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">January 31, 2017</completion_date>
  <primary_completion_date type="Actual">January 31, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Eyes With Severe Ocular Adverse</measure>
    <time_frame>Month 24</time_frame>
    <description>vision loss of 3 or more lines associated with radiation retinopathy or papillopathy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Anti-VEGF Injections Administered</measure>
    <time_frame>Month 24</time_frame>
    <description>efficacy measure</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Exudative Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>24GyE + anti-VEGF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>16GyE + anti-VEGF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Irradiation + anti-VEGF</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>24GyE proton and Anti-VEGF</intervention_name>
    <description>24GyE proton beam will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy</description>
    <arm_group_label>24GyE + anti-VEGF</arm_group_label>
    <other_name>24Gy Proton Beam + Anti-VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>16GyE and anti-VEGF</intervention_name>
    <description>16GyE of Proton Beam Irradiation will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy</description>
    <arm_group_label>16GyE + anti-VEGF</arm_group_label>
    <other_name>16Gy proton beam + Anti-VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham Irradiation and anti-VEGF</intervention_name>
    <description>2 Sessions of Sham Proton Beam Irradiation 24 hrs apart administered 2 to 6 weeks after intravitreal anti-VEGF therapy</description>
    <arm_group_label>Sham Irradiation + anti-VEGF</arm_group_label>
    <other_name>Sham proton beam + anti-VEGF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be eligible if the following criteria are met:

               -  Ability to provide written informed consent and comply with study assessments for
                  the full duration of the study

               -  Age &gt; 50 years

               -  Patient related considerations

               -  Able to maintain follow-up for at least 24 months.

               -  Women must be postmenopausal without a period for at least one year.

               -  Diagnosed with Age-related Macular Degeneration (ARMD) with active subfoveal
                  choroidal neovascular membrane (CNVM), newly diagnosed or treated with first dose
                  of anti-VEGF therapy within 6 weeks of enrollment

               -  Visual acuity 20/40 to 20/400

               -  Lesion size &lt; 12 Disc Area

               -  Submacular hemorrhage less than 75% of total lesion and not involving foveal
                  center

               -  Submacular fibrosis less than 25% of total lesion

               -  Candidate for intravitreal anti-VEGF therapy

        Exclusion Criteria:

          -  Subjects who meet any of the following criteria will be excluded from this study:

               -  Prior enrollment in the study

               -  Pregnancy (positive pregnancy test) or lactation

               -  Any other condition that the investigator believes would pose a significant
                  hazard to the subject if the investigational therapy were initiated

               -  Participation in another simultaneous medical investigation or trial

               -  Previous treatment with Photodynamic Therapy (PDT) or thermal laser in study eye

               -  Anti-VEGF therapy within 6 weeks

               -  Intravitreal or subtenon's Kenalog within 6 months

               -  Intraocular surgery within 3 months or expected in the next 6 months

               -  Current or planned participation in other experimental treatments for wet AMD

               -  Other concurrent retinopathy or optic neuropathy

               -  Other causes of CNVM, i.e. myopic degeneration or ocular histoplasmosis (POHS)

               -  Significant media opacity precluding adequate view of the fundus for exam,
                  photography or OCT

               -  History of radiation therapy to the head or study eye

               -  Diabetes mellitus or hemoglobin A1c &gt; 6

               -  Head tremor or h/o claustrophobia precluding positioning for proton irradiation

               -  Inability to maintain steady fixation with either eye

               -  History of Malignancy treated within 5 years

               -  Allergy to Fluorescein dye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanna S Park, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis Eye Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>September 29, 2010</study_first_submitted>
  <study_first_submitted_qc>September 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2010</study_first_posted>
  <results_first_submitted>May 7, 2018</results_first_submitted>
  <results_first_submitted_qc>June 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 17, 2018</results_first_posted>
  <last_update_submitted>June 19, 2018</last_update_submitted>
  <last_update_submitted_qc>June 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exudative Age-related Macular Degeneration</keyword>
  <keyword>Proton beam irradiation</keyword>
  <keyword>ranibizumab</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>anti-VEGF therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 8, 2010</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT01213082/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>24GyE + Anti-VEGF</title>
          <description>24GyE proton and Anti-VEGF: 24GyE proton beam will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy</description>
        </group>
        <group group_id="P2">
          <title>16GyE + Anti-VEGF</title>
          <description>16GyE and anti-VEGF: 16GyE of Proton Beam Irradiation will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy</description>
        </group>
        <group group_id="P3">
          <title>Sham Irradiation + Anti-VEGF</title>
          <description>Sham Irradiation and anti-VEGF: 2 Sessions of Sham Proton Beam Irradiation 24 hrs apart administered 2 to 6 weeks after intravitreal anti-VEGF therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>24GyE + Anti-VEGF</title>
          <description>24GyE proton and Anti-VEGF: 24GyE proton beam will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy</description>
        </group>
        <group group_id="B2">
          <title>16GyE + Anti-VEGF</title>
          <description>16GyE and anti-VEGF: 16GyE of Proton Beam Irradiation will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy</description>
        </group>
        <group group_id="B3">
          <title>Sham Irradiation + Anti-VEGF</title>
          <description>Sham Irradiation and anti-VEGF: 2 Sessions of Sham Proton Beam Irradiation 24 hrs apart administered 2 to 6 weeks after intravitreal anti-VEGF therapy</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>best corrected visual acuity</title>
          <units>logMAR BCVA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.72" spread="0.39"/>
                    <measurement group_id="B2" value="0.59" spread="0.51"/>
                    <measurement group_id="B3" value="0.55" spread="0.18"/>
                    <measurement group_id="B4" value="0.62" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Eyes With Severe Ocular Adverse</title>
        <description>vision loss of 3 or more lines associated with radiation retinopathy or papillopathy</description>
        <time_frame>Month 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>24GyE PBT</title>
            <description>intravitreal anti-VEGF combined with 24GyE PBT for exudative AMD</description>
          </group>
          <group group_id="O2">
            <title>16GyE PBT</title>
            <description>intravitreal anti-VEGF combined with 16GyE PBT for exudative AMD</description>
          </group>
          <group group_id="O3">
            <title>Sham Radiation</title>
            <description>intravitreal anti-VEGF combined with sham PBT for exudative AMD</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Eyes With Severe Ocular Adverse</title>
          <description>vision loss of 3 or more lines associated with radiation retinopathy or papillopathy</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Anti-VEGF Injections Administered</title>
        <description>efficacy measure</description>
        <time_frame>Month 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>24GyE PBT</title>
            <description>intravitreal anti-VEGF combined with 24GyE PBT for exudative AMD</description>
          </group>
          <group group_id="O2">
            <title>16GyE PBT</title>
            <description>intravitreal anti-VEGF combined with 16GyE PBT for exudative AMD</description>
          </group>
          <group group_id="O3">
            <title>Sham Radiation</title>
            <description>intravitreal anti-VEGF combined with sham PBT for exudative AMD</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Anti-VEGF Injections Administered</title>
          <description>efficacy measure</description>
          <units>number of anti-VEGF injections per eye</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.67" spread="1.9"/>
                    <measurement group_id="O2" value="7.25" spread="2.1"/>
                    <measurement group_id="O3" value="9.67" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>24GyE + Anti-VEGF</title>
          <description>24GyE proton and Anti-VEGF: 24GyE proton beam will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy</description>
        </group>
        <group group_id="E2">
          <title>16GyE + Anti-VEGF</title>
          <description>16GyE and anti-VEGF: 16GyE of Proton Beam Irradiation will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy</description>
        </group>
        <group group_id="E3">
          <title>Sham Irradiation + Anti-VEGF</title>
          <description>Sham Irradiation and anti-VEGF: 2 Sessions of Sham Proton Beam Irradiation 24 hrs apart administered 2 to 6 weeks after intravitreal anti-VEGF therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Mild retinal vasculopathy possible radiation retinopathy</sub_title>
                <description>as accessed at month 24</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>cataract progression due to radiation</sub_title>
                <description>as assessed at month 24</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susanna Park, MD</name_or_title>
      <organization>University of California Davis</organization>
      <phone>9167346074</phone>
      <email>sscpark@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

